EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

A novel cationized agarose-based oral mucoadhesive delivery platform

Angeles Gloria Rodríguez-Basso, Héctor Juan Prado, María Cristina Matulewicz, Silvina Laura Bonafede, Victoria Andrea Vitali, Julián Andrés Fuda, Susana Beatriz Gorzalczany

Ars Pharmaceutica (Internet) · 20.06.2026 · 67 (3) · 299-315

DOI: 10.30827/ars.v67i3.36138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ars Pharmaceutica (Internet), online erschienen am 20.06.2026. Verfasst von Angeles Gloria Rodríguez-Basso und 6 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gallic acid has demonstrated benefits in intestinal inflammatory diseases but exhibits disadvantageous oral pharmacokinetics. This study aims to characterize a novel polyelectrolyte-drug complex involving gallic acid, designed for oral administration to target the intestinal tract.

Methods

The agarose was cationized, complexed with gallic acid and characterized by infrared spectroscopy, nuclear magnetic resonance, scanning electron microscopy and high performance liquid chromatography. Mucoadhesivity, in vitro and in vivo release were also assessed. The antinociceptive activity was measured.

Results

The concentration of gallic acid in the complex was 189.8 ± 1.1 µg/mg. The formulation showed a greater mucoadhesive capacity in normal colon (37.4 ± 2.2 %) and jejunum (24.4 ± 2.5 %) and in damaged colon (139.3 ± 0.9 %), jejunum (24.9 ± 1.4 %), and ileum (17.5 ± 1.6 %). However, the complex decreased its adhesion in the normal stomach (20.8 ± 1.4 %), without any changes in injured stomach and normal ileum. Additionally, in vitro release test increased the release time at pH 6.0 and 7.4 compared with the unformulated compound in the same conditions. In vivo analysis showed improved pharmacokinetic behavior with the complex, meanwhile antinociception activity of gallic acid was preserved.

Conclusions

This oral mucoadhesive system improves the pharmacokinetic behavior of gallic acid and preserves its biological activity, positioning it as a useful strategy for the treatment of intestinal disorders.

Zitieren

APA

Rodríguez-Basso, A. G., Prado, H. J., Matulewicz, M. C., Bonafede, S. L., Vitali, V. A., Fuda, J. A., & Gorzalczany, S. B. (2026). A novel cationized agarose-based oral mucoadhesive delivery platform. Ars Pharmaceutica (Internet), 67(3), 299-315. https://doi.org/10.30827/ars.v67i3.36138

Vancouver

Rodríguez-Basso AG, Prado HJ, Matulewicz MC, Bonafede SL, Vitali VA, Fuda JA, et al. A novel cationized agarose-based oral mucoadhesive delivery platform. Ars Pharmaceutica (Internet). 2026;67(3):299-315. doi:10.30827/ars.v67i3.36138

BibTeX
@article{RodrguezBasso2026,
  author = {Rodríguez-Basso, Angeles Gloria and Prado, Héctor Juan and Matulewicz, María Cristina and Bonafede, Silvina Laura and Vitali, Victoria Andrea and Fuda, Julián Andrés and Gorzalczany, Susana Beatriz},
  title = {A novel cationized agarose-based oral mucoadhesive delivery platform},
  journal = {Ars Pharmaceutica (Internet)},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {299--315},
  doi = {10.30827/ars.v67i3.36138}
}
Kostenlos starten →